IMpower010: OS results of atezolizumab vs best supportive care in resected NSCLC

IMpower010: OS results of atezolizumab vs best supportive care in resected NSCLC

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLCПодробнее

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC

Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLCПодробнее

Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC

Dr Bhuvan | IMpower010 Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB IIIAПодробнее

Dr Bhuvan | IMpower010 Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB IIIA

IMpower010: OS Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in ...Подробнее

IMpower010: OS Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in ...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy ...Подробнее

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy ...

#ESMO21 Highlights on patterns of relapse in NSCLC to atezolizumab vs BSC after adj CT: IMpower010Подробнее

#ESMO21 Highlights on patterns of relapse in NSCLC to atezolizumab vs BSC after adj CT: IMpower010

IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLCПодробнее

IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC

KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLCПодробнее

KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC

ASCO 2021 Lung Recap: IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung CancerПодробнее

ASCO 2021 Lung Recap: IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung Cancer

Assessing the impact of atezolizumab in NSCLCПодробнее

Assessing the impact of atezolizumab in NSCLC

2021 ASCO Direct San Francisco | Local Lung Cancer Summary | Dr. Millie DasПодробнее

2021 ASCO Direct San Francisco | Local Lung Cancer Summary | Dr. Millie Das

JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLCПодробнее

JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLC

Expert Video Report on therapeutic advances in NSCLC from 2021 ASCO Annual MeetingПодробнее

Expert Video Report on therapeutic advances in NSCLC from 2021 ASCO Annual Meeting

Podcast 299: Lung cancer and atezolizumab — results from the IMpower010 trialПодробнее

Podcast 299: Lung cancer and atezolizumab — results from the IMpower010 trial

Dr Taha Sethijiwala IMpower010 Updated data of phase III Trial of adjuvant Atezolizumab vs BSC in ReПодробнее

Dr Taha Sethijiwala IMpower010 Updated data of phase III Trial of adjuvant Atezolizumab vs BSC in Re

Is Disease-Free Survival a Meaningful Endpoint in NSCLC? - Medpage TodayПодробнее

Is Disease-Free Survival a Meaningful Endpoint in NSCLC? - Medpage Today

"IMpower010: TGFB CAF Gene Signature & DFS in NSCLC | Dr. Manoj Mahajan | CRSFПодробнее

'IMpower010: TGFB CAF Gene Signature & DFS in NSCLC | Dr. Manoj Mahajan | CRSF

What Did We Learn From IMpower010 in Resectable NSCLC? - Medpage TodayПодробнее

What Did We Learn From IMpower010 in Resectable NSCLC? - Medpage Today

IMPower 010: Adjuvant Atezolizumab in NSCLC - OncTalk Lung 2023Подробнее

IMPower 010: Adjuvant Atezolizumab in NSCLC - OncTalk Lung 2023